Atlas Trials

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Clinical trial NCT05686629 · UNKNOWN

Trial details

NCT number
NCT05686629
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Novel COVID-19-Infected Pneumonia
Start date
2024-04-01
Primary completion
2025-02-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.